| | 51940-44-4 Basic information More.. |
| Product Name: | Pipemidic acid | | Synonyms: | 8-ETHYL-5,8-DIHYDRO-5-OXO-2-[1-PIPERAZINYL]PYRIDO[2,3-D]-PYRIMIDINE-6-CARBOXYLIC ACID;LABOTEST-BB LT00772244;PIPEMIDIC ACID;1489rb;pipemid;piperamicacid;pipram;pyrido(2,3-d)pyrimidine-6-carboxylicacid,5,8-dihydro-8-ethyl-5-oxo-2-(1-piper | | CAS: | 51940-44-4 | | MF: | C14H17N5O3 | | MW: | 303.32 | | EINECS: | 257-530-2 | | Mol File: | 51940-44-4.mol |  |
Use
An orally administered pyridopyrimidine derivative with a 7-piperazinyl moiety. The piperazinyl moiety at C-7 increases in-vitro activity against Ps. aeruginosa. Pipemidic acid is inactive against Gram-positive bacteria or anaerobes It is well absorbed orally. The drug is rapidly metabolized, primarily to acetyl, formyl and oxo derivatives, which exhibit much reduced antibacterial activity. It is eliminated in the urine, 50–85% of a dose appearing over the first 24 h, less than 2% as inactive metabolites. Non-renal clearance accounts for 10–40% of a dose in the young, rising to 40–70% in elderly subjects, thereby compensating for possible renal insufficiency. No dosage adjustment is necessary in patients with mild renal insufficiency. Some of the drug is eliminated in the bile and a significant portion appears in the feces. Nausea and vomiting are common; dizziness, weakness and grand mal seizures have been observed, principally in the elderly. A number of reactions have been sufficiently severe to require discontinuation of therapy. Clinical use is restricted to urinary tract infections.
- Pipemidic acid
-
- US $0.00-0.00 / g
- 2023-11-03
- CAS:51940-44-4
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100000tons
- Pipemidic acid
-
- US $90.00-70.00 / kg
- 2023-10-20
- CAS:51940-44-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000/month
- Pipemidic acid
-
- US $40.00-40.00 / kg
- 2023-09-07
- CAS:51940-44-4
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 10 tons
|
|
51940-44-4
Recommend Suppliers |
|